U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07037277) titled 'C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV' on June 10.
Brief Summary: The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C, Chronic
Hepatitis C Virus Infection
Hepatitis C
Intervention:
DRUG: Bemnifosbuvir-Ruzasvir
BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
DRUG: Sofosbuvir-Velpat...